. In a healthy, cancer-free prostate, these glands are large and irregularly shaped. However as tumours develop and progress, the epithelial glands become smaller and more rounded or oval. These changes in shape and size of the glands can, potentially, have a drastic effect on the normal secretory pathways, where proteins and lipids are often glycosylated. The process of glycosylation describes the enzymatic conjugation of polysaccharides to proteins, thus producing glycoconjugates to be either secreted, or conjugated to proteins or lipids in the cell membrane.
The physiological function of the prostate is to act as a secretory gland involved in ejaculation, and as such it is a major secretor of glycoproteins of all types. Both the development of the prostate gland, and maintenance of these secretory functions are dependent upon signals from the androgen receptor (AR). In the classical model of androgen signalling, binding of androgens to the AR induces dimerization of the AR and translocation to the nucleus. Once in the nucleus, the AR binds to DNA sequences termed androgen response elements (AREs) that are located within the promoter regions of a number of androgen-regulated genes, including genes encoding cell-cycle regulators and regulators of central metabolism and biosynthesis 3 . Androgen-deprivation therapy (ADT, or chemical castration) is an effective first-line treatment of prostate cancer, which is often initially effective. However recurrences of castration-resistant forms of the disease within 2-3 years can subsequently occur, which are thought to involve persistence of AR signalling and reprogramming of the AR transcriptional landscape 4, 5 . Castration-resistant prostate cancer is ultimately lethal; therefore, an urgent need to identify new diagnostic and therapeutic targets currently exists.
O-linked glycosylation and N-linked glycosylation are the two most common mechanisms by which glycans are linked to proteins (FIG. 1) . In O-linked glycosylation, sugars are added incrementally to the hydroxyl oxygen 1 
Glycans
The carbohydrate moieties of a glycoprotein, glycolipid or a proteoglycan.
O-linked glycans
Oligosaccharides that are covalently linked to a serine or threonine residue via an oxygen atom.
N-linked glycans
Oligosaccharides covalently linked to an asparagine residue of a protein via a nitrogen atom.
Glycome
The global collection of glycans (sugar chains) synthesized by a cell.
Glycosyltransferases
Enzymes that catalyse the transfer of sugars (saccharides) to proteins, lipids or carbohydrates, forming covalent bonds.
Lectins
Carbohydrate binding proteins that are highly specific for sugar moieties.
of serine and/or threonine residues on the target protein, whereas in N-linked glycosylation, preassembled blocks of 14 sugars are transferred co-translationally via the amide group of an asparagine residue on the target protein. Hence glycans are attached to proteins via an oxygen atom of a serine or threonine residue (O-linked glycan), or a nitrogen atom of an asparagine residue (N-linked glycan). These post-translational modifications occur as a consequence of the synchronized action of glycosyltransferase and glycosidase enzymes and take place in the Golgi apparatus and the lumen of the endoplasmic reticulum
In mammals, nine different sugar-nucleotide donors that supply polysaccharides for glycosylation have been identified: uridine diphosphate (UDP)-glucose, UDP-galactose, guanosine diphosphate (GDP)-mannose, GDP-fucose, UDP-xylose, UDP-glucuronic acid, cytidine monophosphate (CMP)-sialic acid, UDP-N-acetyl-galactosamine (UDP-GalNAc) and UDP-N-acetyl-glucosamine (UDPGlcNAc) 6 . The expression and activity of the glycosyltransferase and glycosidase enzymes determines the cellular glycome, which adds intrinsic diversity to the information encoded by the genome, transcriptome and proteome.
Alterations in glycosylation patterns in cancerous versus non-cancerous cells were first described >60 years ago 7, 8 , and were later confirmed following the development of monoclonal antibodies against oncofetal antigens that are present on tumour glycoproteins [9] [10] [11] [12] . Cancer cells display numerous alterations in glycosylation patterns compared with non-malignant tissue; these alterations can be caused by altered expression or mislocalization of glycosyltransferases, and differences in the availability of acceptor substrates, sugar nucleotide donors and cofactors in cancer cells. The most frequently observed changes in cancer-associated glycosylation include sialylation, fucosylation, truncation of O-glycans and glycan branching. Cancer progression leads to dramatic changes to the glycoproteome, and tumour-secreted glycoproteins might reflect the altered glycosylation pattern of cancer cells, and are, therefore, potential biomarker candidates 13. Glycosylation of PSA One of the principal functions of the prostate is to produce prostate-specific antigen (PSA), a serine protease that liquefies semen and enhances sperm motility 14 . PSA is a glycoprotein and serum levels of PSA have, historically, been widely used as a biomarker of prostate cancer 15, 16 . During the early stages of prostate cancer, disruption of the prostatic epithelium allows PSA to leak into circulating blood; however, research from the past decade has suggested that serum PSA levels do not effectively distinguish between prostate cancer and other prostatic conditions such as benign prostate hyperplasia (BPH) 1, 17 . Several studies have been conducted to investigate whether a tumour-specific glycan signature on PSA can be used to distinguish between men with prostate cancer and those with BPH, with the goal of developing a more reliable diagnostic test for prostate cancer than serum PSA level 18, 19 . Initial studies compared the glycans detected on PSA from the seminal fluid of healthy donors to PSA purified from the LNCaP cell line [20] [21] [22] . PSA-associated glycans from LNCaP cells were found to have a decreased sialic acid content and an increased fucose and N-acetylgalactosamine content 22 . In numerous other studies, investigators have compared serum or seminal plasma derived PSA obtained from patients with prostate cancer of different disease stages [23] [24] [25] [26] [27] [28] . Increased fucosylation 25 and increased levels of α2,3-linked sialic acid 22, 24, 29 have been observed on serum PSA from patients with prostate cancer compared with serum PSA from patients with BPH. Thus, detection of PSA subforms containing a higher proportion of α2,3-linked sialic acid using 2D electrophoresis supports the use of PSA sialylation as a biomarker to distinguish between prostate cancer and BPH 27, 28 . Differential binding of PSA in serum to lectins that recognize specific glycoforms can also help improve disease stratification. A trend of increased fucose binding with PSA from prostate tissue that increases in proportion to tumour aggressiveness has been observed, and is thought to be mediated by the lectin Ulex Europaeus (UEA), which recognizes fucose, and could help distinguish indolent from more-aggressive tumours 30 . Investigators have also found an increase in O-linked glycosylation with the sialyl Lewis X (SLe x ) antigen on PSA from malignant, compared with adjacent non-malignant tissues in prostate tissue samples from patients that underwent radical prostatectomy 31 . PSA has a single N-glycosylation site at asparagine (Asn)-69, which has been the target of multiple characterization studies 18 . In 2013, the results of a comprehensive multi-laboratory study designed to investigate N-glycosylation of Asn-69 in healthy donors were reported 32 . The participating laboratories used three main approaches including determining the specific glycoforms present on intact PSA glycoproteins, a PSA glycopeptide analysis to determine glycans attached to a protease-digested preparation, and analysis of the glycans after PNGaseF digestion. Data from these studies cumulatively suggest possible glycan structures that could be attached to PSA, the most abundant of which were four biantennary glycans, estimated to comprise approximately 80% of the total number of PSA-bound glycans. These four abundant glycans all have a biantennary Hex5 (consisting of three mannose and two galactose subunits/ Hex-N-acetylglucosamine (NAc)-4 (consisting of four GlcNAc subunits) composition, and contain either one or two sialic acid residues, in the presence or absence of a core fucose subunit (FIG. 2) . Studies designed to analyse the crystal structure of PSA in clinical samples from patients with prostate cancer have also identified larger triantennary and tetra-antennary glycans 20, 23, 33 . The presence of these larger glycans might reflect the disease status of the patients with prostate cancer. However, shifts in N-glycan profile have been linked with human ageing 34 ; therefore, controlling for donor age should be an important consideration of any future studies.
Another biomarker of prostate cancer, prostatic acid phosphatase (PAP), is abundant in prostate tissue, and was previously used to monitor and assess the progression of prostate cancer, before being replaced by serum PSA. Research has shown that PAP from patients with prostate cancer has more non-fucosylated structures and fewer high-mannose chains than PAP from patients with BPH 35 , and increased core-2-linked sialyl Lewis X (SLe X ) compared with non-malignant prostate tissue samples from patients who underwent radical prostatectomy 31 . Both serum-derived and tissue-derived PSA and PAP are attractive targets for analyses of glycopathology; however, for this to be confirmed, the number of clinical samples analysed must increase, and, ultimately, the structure of these cancer-associated glycopeptides needs to be determined.
Sialyl-Tn can affect adhesion
The cancer-associated glycans detected on prostate cancer cells are suggested to result from incomplete synthesis and neo-synthesis processes 9, 36 . In general, incomplete synthesis occurs more often in the early stages of cancer, whereas neo-synthesis is more commonly observed in the more-advanced stages 37 . The incomplete synthesis process is a result of the impairment of normal complex glycan synthesis and leads to the biosynthesis of truncated structures such as the Tn and the sialyl-Tn (sTn) antigen 38 (FIG. 3) . The presence of sTn in serum or tumour tissue biopsy samples has been linked with cancer progression and inferior survival in patients with breast or ovarian cancer [39] [40] [41] [42] , and in patients with prostate cancer, the expression of sTn-Mucin-1 (MUC1), a cell-surface adhesion protein, has been negatively correlated with survival outcomes and positively correlated with serum PSA levels 43 . The formation of the sTn antigen is catalysed by the sialyltransferase α-GalNAc α-2,6-sialyltransferase (ST6GalNAc1), an enzyme that catalyses the transfer of a sialic acid molecule in an α-2-6 linkage onto the Tn antigen (resulting in GalNAc1-O-serine/threonine) 44, 45 . Increased expression of sialylated antigens can inhibit cellular adhesion and promote cell detachment from the tumour, owing to electrostatic repulsion of negative charges. Data published in 2015 have demonstrated that expression of both ST6GalNAc1 and the sTn antigen by prostate cancer cells is induced by androgens (FIG. 4) , and can influence cell adhesion and transition to a more mesenchymal phenotype in a mouse model of prostate cancer 44 . These results are important, as the sTn antigen is detected in up to half of all high-grade prostate cancer tissue samples from patients with this disease 46, 47 . In in vivo mouse models of breast or gastric cancer, expression of ST6GalNAc1 is associated with increased tumour growth and metastasis 48, 49 ; however, in DU145 prostate cancer cells, stable expression of ST6GalNAc1 dramatically hindered the formation of stable tumour masses in vivo and did not influence metastasis in a mouse model 44 . Interestingly, expression of ST6GalNAc1 is increased in primary prostate tumours, although this expression is downregulated in metastatic tissue relative to non-malignant prostate tissue 44 . These results are consistent with a 'reprogramming' of the interactions of the AR with the genome during prostate cancer progression 5 , and indicate that ST6GalNAc1 might have a transient role in tumour progression 44 . As seen in patients with other types of cancer, prostate cancer cells also express the Tn antigen (GalNAc-O-Ser/Thr) on their cell surface. The exact 
Box 1 | Enzymes involved in glycosylation
The importance of the process of glycosylation is reflected by the high number of genes involved in the synthesis, processing, modification, binding and degradation of glycans. The synthesis of glycans is determined by glycosyltransferases, which catalyse the assembly of sugar moieties into linear and branched glycan structures and act sequentially so that the product of one enzyme yields a preferred acceptor substrate for the subsequent modification by another enzyme 36 . Some of the enzymes with roles in glycan biosynthesis include glycosidases that remove monosaccharides to form intermediates that are then further modified by glycosyltransferases. This type of processing is particularly relevant to the formation of N-glycans where the nasent glycoprotein Glc 3 Man 9 GlcNAc 2 is sequentially trimmed by mannosidases and glucosidases before further modification by glycosyltransferases to produce complex and hybrid N-glycan chains 117 . Glycans can also be modified in numerous other ways including for example by sulfotransferases, O-acetyltransferases and O-methyltransferases 118 .
role of this form of glycosylation in prostate cancer is unknown, although it has been proposed as a target of immunotherapy in other forms of cancer 50 . 
Sialyl Lewis X

Fucosylation
Fucosylation describes the attachment of a fucose residue to a glycan, and can be divided into terminal fucosylation, which gives rise to specific blood group antigens such as SLe A and SLe X , and core fucosylation, which creates a non-extendable modification 58 . Increased core fucosylation of glycans has been detected in the serum of patients with prostate cancer compared with that of patients with BPH, or of men with no established prostatic disease [59] [60] [61] . Furthermore, fucosylation of glycans is increased in the androgen-independent PC3 prostate cancer cell line relative to that of the androgen-dependent LNCaP cell line 62 . Fucosylated glycans are generated by a range of fucosyltransferases. Expression of the fucosyltransferase FUT8 is increased in prostate cancer metastases and is associated with aggressive disease 63 , and expression of FUTs 3, 6 and 7 might influence prostate cancer cell trafficking through an E-selectin dependent mechanism 64 ; furthermore, upregulation of FUT8 has been found to increase migration of androgen-dependent LNCaP cells, while loss of FUT8 decreased the motility of androgen-independent PC3 cells, suggesting an association with aggressive prostate cancer 63 .
Branched N-glycans β-1,6-GlcNAc tri-branched and tetra-branched N-glycans are frequently overexpressed in cell line xenograft mouse models of prostate cancer 65 . α-1,6-mannosylglycoprotein 6-β-N-acetylglucosaminyltransferase A (MGAT5), which initiates β-1,6-GlcNAc branching, has been suggested to have a role in metastasis 66 . High-throughput, comprehensive serum N-glycan profiling has been used to investigate the utility of serum N-glycans as a predictive biomarker. Patients with castration-resistant prostate cancer have been found to have both increased transcription levels of N-glycan branching enzymes and increased tri-antennary and tetra-antennary N-glycans 61, 67 (FIG. 5a) .
Cryptic N-glycans
Cryptic N-glycans occur as a result of alterations in the normal biosynthesis and processing of glycans 68 and are high-mannose structures that would normally be processed to more complex structures, N-glycan precursors, or complex N-glycans, but do not undergo further modifications with galactose or sialic acid 69 . Cryptic N-glycans are normally masked by other sugar moieties, and, as such, are normally hidden by extensive saccharide branching but become exposed in cancer cells. Cryptic N-glycans might be relevant to the progression of prostate cancer. The presence of cryptic N-glycans has been detected in patients with advanced-stage prostate tumours, with a greater abundance of autoantibodies to the cryptic N-glycan Man9 observed in serum from patients with advanced-stage prostate cancer, compared with serum from patients with BPH, or from those with earlier-stage prostate cancer 70 (FIG. 5b) . Further development of assays to detect anti-Man9 antibodies in serum samples will likely provide a useful clinical tool in the future.
Glycosphingolipids
Many of the core-O-glycan structural motifs found on glycoproteins are also found on glycosphingolipids, which are glycans linked to a lipid ceramide moiety. Glycosphingolipids that contain sialic acid are known Gal Mannose Nature Reviews | Urology as gangliosides. Ganglioside GD1a has been reported to be abundantly produced in several prostate cancer cell lines, and in tissue samples from patients with castration-resistant prostate cancer 71, 72 ; however, further analyses of GD1a production in prostate cancer tissue and model systems is needed. The F77 antigen has been linked with progression of prostate cancer and, in 2014, was characterized as a glycolipid with α1,2-fucose linkages 73, 74 . The F77 antibody was initially isolated from mice after injection of PC3 cells and provoked great interest, owing to its potential as a diagnostic and possibly therapeutic tool 75, 76 . The F77 antibody was found to stain 112 of 116 primary prostate tissue samples and 29 of 34 metastatic tissue samples with minimal staining of non-malignant prostate tissue 76 , and to inhibit the growth of PC3 or DU145 tumour xenografts in nude mice 76 . The glycosyltransferases FUT1, GCNT1, GCNT2 and GCNT3, have been identified as being responsible for the synthesis of the F77 antigen, possibly via a hypoxia-induced mechanism 73, 74 . Notably, the core-2-glycosyltransferase GCNT1 is upregulated in prostate cancer tissue compared with non-malignant tissue and has been linked with disease progression 31, 77 .
Proteoglycans
Proteoglycans are glycoconjugates that contain glycosaminoglycans (GAGs) such as chondroitin sulfate, heparin sulfate and keratin sulfate 37 . Proteoglycans are important components of the tissue stroma and extracellular matrices of the prostate gland 78 . Proteoglycans can act as key molecular effectors at the cell surface and in the pericellular microenvironment, and also have a role in cancer progression owing to their ability to interact with both ligands and receptors, and thus mediate a diverse range of effects 79, 80 . Data from a range of studies suggest that alterations in proteoglycan composition and function can promote both the survival of prostate cancer cells and metastasis 81 . The role of several proteoglycans in the development of prostate cancer has been investigated, including that of the extracellular proteoglycans decorin, perlecan and versican, and the cell-surface proteoglycan syndecan-1 (REFS 81, 82) .
Proteoglycans can have both protumourigenic and antitumorigenic effects upon prostate cancer progression. The small, leucine-rich proteoglycan decorin has been shown to suppress prostate tumour growth through inhibition of both AR and phosphatidylinositol 3-kinase (PI3K) signalling. Findings of transcript-profiling studies have shown that decorin expression is reduced in the prostate-cancer-associated stroma of human prostate cancer samples, and administration of decorin could be a promising future treatment of patients with PTENnegative prostate cancers 83, 84 . Conversely, expression of the basement-membrane proteoglycan perlecan is associ ated with disease progression; suppression of perlecan expression in cell lines using siRNA decreases sonic hedgehog signalling and reduces LNCaP cell growth, suggesting that perlecan might act as a tumour promoter through upregulation of sonic hedgehog signalling 85 . Increased levels of versican, a large chondroitin sulfate proteoglycan, are also associated with poor outcomes in patients with one of several types of cancer, including prostate cancer [86] [87] [88] [89] . Versican modulates binding to various components of the extracellular matrix and enhances the motility of prostate cancer cells 90 . Specific alterations to chondroitin sulfate side chains might be crucial for disease progression in patients with prostate cancer, and could have important prognostic implications for disease progression, especially if combined with other clinical measures such as tumour Gleason score and serum PSA levels [91] [92] [93] . The cell-surface proteoglycan syndecan-1 might also have a role in cancer progression. Syndecan-1 has been identified as a key molecule in maintaining the stability of prostate tumour-initiating cells 94 , and thus might have a role in epithelial-to-mesenchymal transition and, therefore, the progression of prostate cancer 95, 96 . Further study of the role of proteoglycans in the development and progression of prostate cancer will help improve our knowledge of both the prostate tumour cell microenvironment and the role of epithelial-stromal cell interactions in prostate cancer progression. Proteoglycan expression patterns might also be useful as predictive and prognostic biomarkers in patients with prostate tumours.
Upregulated HBP in prostate cancer
The hexosamine biosynthesis pathway (HBP) (FIG. 6) is sustained by metabolites sourced from the major metabolic processes in the cell, such as glutamine, acetyl coenzyme A, glucose and uridine 94 , and has emerged as a major metabolic integration point influencing a range of 
Proteoglycans
Proteins with one or more glycosaminoglycan (GAG) chains, such as chondroitin sulfate and heparin sulfate. Proteoglycans constitute a large fraction of the extracellular matrix and have key roles in cell adhesion and motility.
processes involved in the cell cycle, cell growth, metabolism and stress 97, 98 . The HBP produces UDP-GlcNAc, an amino-sugar conjugate that provides a substrate for the post-translational modification of both plasma membrane and secretory proteins. UDP-GlcNAc can be conjugated to target proteins in several ways: glycosylation catalysed by O-GlcNAc transferase (OGT) in the cytoplasm, nucleus and mitochondria 99 , and O-linked and N-linked glycosylation occurring in the Golgi apparatus and endoplasmic reticulum, resulting in complex sugar conjugates on the target proteins 100 . Upregulated expression of OGT in patients with prostate cancer correlates with a higher tumour Gleason score and an increased risk of biochemical recurrence 101, 102 and elevated O-GlcNAc is associated with a poor prognosis, relative to that of patients with lower levels of O-GlcNAc expression 103 . OGT catalyses the glycosylation of and, therefore, modifies the function of a range of target proteins. Key targets of OGT include transcription factors such as c-MYC and FOXM1 (REF. 101 ). Hence increased activity of OGT in patients with prostate cancer might promote metabolic reprogramming of tumour cells in combination with gains in MYC copy number, and, therefore, has important transcriptional consequences 101, 102, 104 . The last enzyme in the HBP pathway, UDP-Nacetylglucosamine pyrophosphorylase 1 (UAP1), is highly overexpressed in tumour tissue samples from patients with prostate cancer. UAP1 expression is regulated by AR activity and has been shown to be negatively correlated with tumour Gleason score and positively with AR expression 104 . Data from in vitro experiments indicate that high UAP1 expression and/or HBP activity is protective against inhibition of N-linked glycosylation 104 .
Upregulation of glycosylation enzymes
Differential expression of glycosyltransferases and glycosidases involved in the synthesis and catabolism of glycans is a primary contributor to the aberrant glycosylation observed in tumour samples from patients with prostate cancer 30 . Growing evidence exists linking differential expression of glycosylation enzymes with the progression of prostate cancer 31, 44, 101, [104] [105] [106] . In a meta-analysis of clinical prostate cancer gene expression data published in 2014, investigators identified a novel 33-gene set containing four genes that encode glycosylating enzymes: ST6GALNAC1, GCNT1, UDP N-acetylglucosamine pyrophosphorylase 1 (UAP1) and β-1,3-glucuronyltransferase 1 (B3GAT1) whose expression was upregulated 106 . As discussed above, ST6GALNAC1, which encodes a sialyltransferase enzyme, is upregulated in mouse models of prostate cancer 44 . ST6GalNAc1 synthesizes the sTn antigen and has been shown to reduce prostate cancer cell adhesion 44 . UAP1 is the last enzyme in the HBP pathway and is highly overexpressed in tissue samples from patients with prostate cancer 105 . GCNT1 cata lyses the formation of core-2-branched O-linked glycans, and has previously been shown to be an independent predictor of prostate cancer recurrence; furthermore, a positive correlation exists between increased GCNT1 expression and more aggressive disease 78 . GCNT1 is also implicated in the production of the F77 prostate cancer antigen 74, 75 and with altered O-glycosylation of PSA, PAP, and MUC1 (REF. 31 ). Upregulation of both GCNT1 and ST6GALNAC1 is frequently detected in the same tissue samples 44 and upregulation of these genes has been observed as part of a glycosylation signature containing genes that encode five other glycosylation enzymes, GALNT7, GALNT3, B4GALT3, MOGS and EDEM3 (REF. 31 ). These results suggest that understanding how changes in the expression and activity of glycosylation enzymes function coordinately with each other rather than in isolation to modify the cellular behaviour of prostate cancer cells.
Future perspectives
Patterns of glycosylation change in many cancers, and data from emerging studies, suggest that the functional and prognostic relevance of some glycans might be unique to prostate cancer, among other human adenocarcinomas. Positive binding of Helix pomatia agglutinin (HPA) lectin is associated with disease progression and metastasis in a range of cancer types [108] [109] [110] [111] ; however, in prostate cancer, binding of HPA is reduced in metastatic disease and HPA-negative tumours have poorer overall survival and faster progression 112 . Data from several studies suggest that expression of the ST6GalNAc1 enzyme in breast and colon cancer cell lines increases tumour growth, although in prostate cancer cells ST6GalNAC1 expression inhibits the formation of solid tumour masses 44, 48, 49 . Together with the abundance of changes in glycosylation patterns detected in prostate cancer, these data suggest that some as yet undefined feature of glycosylation exists that is unique to prostate tissue. The emerging direct link between the AR and the expression of key glycosylation enzymes provides a candidate for this direct link. Expression of the HBP pathway enzyme UAP1 is directly regulated by the AR in prostate cancer cells 105 . Similarly, expression of ST6GalNAc1, the enzyme responsible for synthesizing the sTn antigen, is also a direct transcriptional target of the AR 44 . Some of the unique features of the glycans associated with prostate cancer might, at least in part, be a result of AR-mediated changes to the prostate cancer glycoproteome. An alternative explanation is that the overall change in the prostate glycoproteome induced by cancer is multifactorial and we need to evalu ate the influence of each glycosylation enzyme in a context where multiple other glycosylation enzymes are also dysregulated.
Current methods to evaluate changes in glycosylation in prostate tissue usually involve homogenization and extraction of glycans and glycoproteins for ana lysis using mass spectrometry or antibody/lectin arrays, meaning that any spatial or histopathological information is usually lost. Broad-affinity carbohydrate-binding lectins can be used to examine the specific glycan structures present in prostate tissue samples; however, this approach does not enable individual glycan species to be determined. In the past 3 years, a method of directly profiling N-linked glycans directly on formalin-fixed, paraffin-embedded (FFPE) tissue samples and tissue microarrays has been developed 19, 113, 114 . A molecular coating of the amidase PNGaseF is sprayed directly onto the FPFE tissue sample and the released glycans are analysed using a high-resolution matrix-assisted laser desorption/ionization-Fourier transform ion cyclotron resonance detection instrument. Using this approach, the ion signal intensities of each released glycan at each tissue location are determined and converted to a heat map. FFPE tissues are usually readily available in pathology labs; therefore, this technique holds particular promise. This approach has been used to detect the presence of cryptic glycan species, high mannose N-glycans, and glycans attached to PSA, and has the potential to identify novel biomarker panels of individual glycan species for both detection and prognosis of prostate cancer 19, 113, 114 . Glycomics analysis of serum and plasma samples from patients with prostate cancer has produced promising results in terms of distinguishing samples from patients with prostate cancer from those derived from individuals without the disease 62, 115 . Evaluation of 
O-GlcNAcylation
Addition of N-acetylglucosamine (GlcNAc) to serine or threonine residues on nuclear and cytoplasmic proteins.
changes in the glycosylation of exosome glycoproteins isolated from serum samples or from expressed-prostatic secretions has also shown promise as an alternative approach 116 . In future, these potential approaches will likely be evaluated further using a larger number of clinical samples.
Conclusions
The existence of substantial heterogeneity in outcomes observed in different patients poses an important clinical challenge to the management and prognosis of patients with prostate cancer; however, determining the differences between indolent (not necessarily lethal) and aggressive disease is currently very difficult. What factors make some prostate cancers grow slowly relative to other, more-aggressive tumours is largely not understood, nor do we understand why prostate cancer tends to metastasize to bone substantially more frequently than to other organs. Glycoproteins and glycan composition is likely to have an important role in these processes; therefore, understanding their function and composition in both the non-malignant prostate and in prostate cancer will likely be vital in terms of improving the management of patients with this disease.
